Cardiac Science
This article was originally published in The Gray Sheet
Executive Summary
Nets over $1 mil. from private placement through Beverly Hills-based investment banking firm H.J. Meyers. Cardiac Science will use a portion of the funds to initiate clinical trials of its Powerheart 360j automatic external cardioverter defibrillator, a non-surgical bedside device. FDA recently approved an investigational device exemption submitted by Cardiac Science in April ("The Gray Sheet" May 11, p. 14). Cardiac Science also will use the funds to develop ambulatory models of the device, including a vest-worn version....